English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Continuous Glucose Monitors (CGM) has revolutionized the management of diabetes and has become the standard of care for the management of Type 1 diabetes. The primary factor preventing widespread uptake of CGM is cost. Currently there is little provincial coverage for CGM, and many patients still must pay for the technology. The cost of CGM is here evaluated in comparison to standard care (self monitoring of blood glucose), including analysis of cost-savings and improvements in quality of life that could be achieved with the use of CGM. When costs of comorbidities and absenteeism that could be reduced by the use of CGM are included in the analysis, it is determined that CGM is cost-neutral relative to standard care.

Continuous Glucose Monitors are Cost Neutral Compared to SMBG